Neurocrine Biosciences Analyst Ratings
Morgan Stanley Keeps Their Buy Rating on Neurocrine (NBIX)
Neurocrine Biosciences Analyst Ratings
Buy Rating Affirmed for Neurocrine Biosciences on Strong Drug Pipeline and Promising Schizophrenia Treatment Prospects
RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating
Maintaining Hold on Neurocrine Biosciences Amid Efficacy Concerns and Competitive Pressures
Neurocrine Biosciences Analyst Ratings
Neurocrine Biosciences Analyst Ratings
Neurocrine Biosciences Analyst Ratings
Neurocrine Biosciences Analyst Ratings
Neurocrine Biosciences Analyst Ratings
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $170
Neurocrine Biosciences Analyst Ratings
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating
Oppenheimer Sticks to Its Buy Rating for Neurocrine (NBIX)
Buy Rating Affirmed for Neurocrine Biosciences on Strong Performance and Promising Pipeline
Neurocrine Biosciences Analyst Ratings
RBC Capital Remains a Hold on Neurocrine (NBIX)
Neurocrine Biosciences Upgraded at Wells Fargo on Pipeline
Jefferies Sticks to Its Buy Rating for Neurocrine (NBIX)